GATA

Accueil > LYSA > GATA

GATA

Etude de la combinaison de l'Atezolizumab avec le Venetoclax et l'Obinutuzumab dans les lymphomes B en rechute ou réfractaire (phase Ib-II) rechute ou réfractaire (phase Ib-II)
Poster GATA ASCO 2021
Charles Herbaux

Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA

 

Abstract
Communication orale GATA EHA 2021
Charles Herbaux

Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA

 

Abstract
Poster GATA EHA 2021
Yassine Al Tabaa

Prospective Evaluation of Lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA Group

 

Abstract
Posters GATA ICMLugano 2021
Charles Herbaux

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA

 

ICMLugano Charles Herbaux Abstract N°145
Guillaume Cartron

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA

 

ICMLugano Guillaume Cartron Abstract N°110
Yassine Al Tabaa

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA group

 

ICMLugano Yassine Al Tabaa Abstract N° 245
Abstract book GATA ICMLugano 2021
Camille Laurent

A widespread T-cell exhaustion pattern is frequent in the tumor microenvironment of relapsed/refractory B-cell Lymphoma patients and could be circumvented by PDL1 blockade

 

ICMLugano Camille Laurent Abstract N°297
Poster GATA ASCO 2020
Charles Herbaux

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA

 

Abstract
Communication orale GATA EHA 2020
Charles Herbaux

Efficacy and Safety of Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Diffuse Large B-Cell Lymphomas: Primary analysis of a Phase 2 trial from LYSA

 

Abstract